pamidronate has been researched along with Lung Neoplasms in 34 studies
Lung Neoplasms: Tumors or cancer of the LUNG.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Intravenous injection of 4 mg zoledronic acid can significantly reduce bone pain and bone resorption marker in urine in the Chinese patients with bone metastasis from solid tumor or multiple myeloma, which is tolerable and also comparable to pamidronate in the efficacy and safety." | 9.13 | [Phase III clinical study of zoledronic acid in the treatment of pain induced by bone metastasis from solid tumor or multiple myeloma]. ( Chen, Q; Dong, M; Feng, FY; Feng, JF; Jiao, SC; Li, J; Liu, JW; Ren, J; Song, ST; Wang, XW; Wang, YJ; Wang, ZH; Xie, GR; Xu, N; Zhang, Y; Zhou, QH, 2008) |
| "Clinical studies showed that pamidronate has curative effects on pain induced by bone metastasis." | 9.11 | [Pamidronate in treatment of pain caused by bone metastasis]. ( Cai, Y; Chen, YL; Liu, HQ; Liu, MZ; Ren, J; Wang, DJ; Zhan, QY, 2004) |
| "We assessed the effects of 60-mg single doses of pamidronate disodium compared with saline alone in the treatment of cancer-associated hypercalcemia." | 9.07 | Treatment of cancer-associated hypercalcemia. Double-blind comparison of rapid and slow intravenous infusion regimens of pamidronate disodium and saline alone. ( Ahmann, F; Chapman, R; Gill, I; Gucalp, R; Heffernan, M; Knight, RD; Madajewicz, S; Navari, R; Theriault, R; Zelenakas, K, 1994) |
| " He was treated with seven courses of combined chemotherapy (CDDP + etoposide), until he showed extreme hypercalcemia and acute renal failure." | 7.70 | [A case of lung cancer with hypercalcemia and renal failure responsive to pamidronate]. ( Kametani, T; Koshida, H; Masuda, S, 1999) |
| "Pamidronate is a second generation bisphosphonate used for treating tumor-induced hypercalcemia and for preventing the development of new bone metastasis." | 7.69 | [Effect of pamidronate and interferon-alpha on bone and lung metastases and hypercalcemia in a patient with renal cell carcinoma]. ( Arima, K; Hioki, T; Kawamura, J; Kise, H; Kobayashi, K; Sugiura, Y; Tochigi, H; Yanagawa, M, 1996) |
| "Treatment with pamidronate, an inhibitor of osteoclastic bone resorption, given every 2 weeks by i." | 5.31 | Pamidronate-induced remission of pain associated with hypertrophic pulmonary osteoarthropathy in chemoendocrine therapy-refractory inoperable metastatic breast carcinoma. ( Naito, Y; Sakurai, T; Suzuma, T; Tamaki, T; Umemura, T; Yoshimasu, T; Yoshimura, G, 2001) |
| "Intravenous injection of 4 mg zoledronic acid can significantly reduce bone pain and bone resorption marker in urine in the Chinese patients with bone metastasis from solid tumor or multiple myeloma, which is tolerable and also comparable to pamidronate in the efficacy and safety." | 5.13 | [Phase III clinical study of zoledronic acid in the treatment of pain induced by bone metastasis from solid tumor or multiple myeloma]. ( Chen, Q; Dong, M; Feng, FY; Feng, JF; Jiao, SC; Li, J; Liu, JW; Ren, J; Song, ST; Wang, XW; Wang, YJ; Wang, ZH; Xie, GR; Xu, N; Zhang, Y; Zhou, QH, 2008) |
| "Clinical studies showed that pamidronate has curative effects on pain induced by bone metastasis." | 5.11 | [Pamidronate in treatment of pain caused by bone metastasis]. ( Cai, Y; Chen, YL; Liu, HQ; Liu, MZ; Ren, J; Wang, DJ; Zhan, QY, 2004) |
| "We assessed the effects of 60-mg single doses of pamidronate disodium compared with saline alone in the treatment of cancer-associated hypercalcemia." | 5.07 | Treatment of cancer-associated hypercalcemia. Double-blind comparison of rapid and slow intravenous infusion regimens of pamidronate disodium and saline alone. ( Ahmann, F; Chapman, R; Gill, I; Gucalp, R; Heffernan, M; Knight, RD; Madajewicz, S; Navari, R; Theriault, R; Zelenakas, K, 1994) |
| "Zoledronic acid (Zometa is a third-generation nitrogen-containing parenteral bisphosphonate indicated for the treatment of bone metastases due to solid tumours or multiple myeloma and for hypercalcaemia of malignancy (HCM)." | 4.84 | Zoledronic acid: a pharmacoeconomic review of its use in the management of bone metastases. ( McKeage, K; Plosker, GL, 2008) |
| " Followed by hydration with saline, pamidronate is effective for the control of symptomatic hypercalcemia." | 4.79 | [Paraneoplastic syndrome]. ( Hara, N; Nakanishi, Y; Takayama, K, 1997) |
| " He was treated with seven courses of combined chemotherapy (CDDP + etoposide), until he showed extreme hypercalcemia and acute renal failure." | 3.70 | [A case of lung cancer with hypercalcemia and renal failure responsive to pamidronate]. ( Kametani, T; Koshida, H; Masuda, S, 1999) |
| "Pamidronate is a second generation bisphosphonate used for treating tumor-induced hypercalcemia and for preventing the development of new bone metastasis." | 3.69 | [Effect of pamidronate and interferon-alpha on bone and lung metastases and hypercalcemia in a patient with renal cell carcinoma]. ( Arima, K; Hioki, T; Kawamura, J; Kise, H; Kobayashi, K; Sugiura, Y; Tochigi, H; Yanagawa, M, 1996) |
| "Hypercalcemia is mainly caused by bone resorption due to either secretion of cytokines including parathyroid hormone-related protein (PTHrP) or bone metastases." | 1.38 | Impact of chemotherapy on hypercalcemia in breast and lung cancer patients. ( Hassali, MA; Hassan, BA; Othman, SB; Weiderpass, E; Yusoff, ZB, 2012) |
| "Pamidronate was well tolerated and only grade 1 or 2 toxicities were registered." | 1.35 | Routine use of pamidronate in NSCLC patients with bone metastasis: results from a retrospective analysis. ( Mitterer, M; Seeber, A; Spizzo, G, 2009) |
| "We report a renal cell carcinoma case in which multiple lung and bone metastases displayed remarkable remission to BP therapy using 30 mg pamidronate once, 4 mg zoledronate once, and weekly 10 mg incadronate 10 times for 3 months." | 1.35 | Lung and bone metastases from renal cell carcinoma responsive to bisphosphonates: a case report. ( Fujii, Y; Fukui, I; Kijima, T; Okubo, Y; Suyama, T; Yonese, J, 2008) |
| "We report on a patient with parathyroid carcinoma with hypercalcaemia and pulmonary metastases, treated with pamidronate and radiotherapy and later with surgery." | 1.31 | Positive effect of radiotherapy and surgery on hormonally active pulmonary metastases of primary parathyroid carcinoma. ( Boquist, L; Kristoffersson, A; Rasmuson, T, 2000) |
| "Treatment with pamidronate, an inhibitor of osteoclastic bone resorption, given every 2 weeks by i." | 1.31 | Pamidronate-induced remission of pain associated with hypertrophic pulmonary osteoarthropathy in chemoendocrine therapy-refractory inoperable metastatic breast carcinoma. ( Naito, Y; Sakurai, T; Suzuma, T; Tamaki, T; Umemura, T; Yoshimasu, T; Yoshimura, G, 2001) |
| "Pamidronate appears to be an effective therapy for HPOA." | 1.30 | The use of pamidronate in hypertrophic pulmonary osteoarthropathy (HPOA). ( Francis, H; Nicklason, F; Speden, D; Ward, J, 1997) |
| "A 57-year-old man with lung squamous cell carcinoma revealed hypercalcemia, hypophosphoremia, elevation of nephrogenous cAMP and metabolic alkalosis." | 1.29 | A case of squamous cell lung carcinoma with high concentration of parathyroid hormone-related peptide in serum and pleural effusion presenting hypercalcemia. ( Haji, M; Hara, N; Ichinose, Y; Iguchi, H; Katakami, H; Nawata, H; Nishi, Y; Ohta, M; Tanaka, S, 1993) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 3 (8.82) | 18.7374 |
| 1990's | 12 (35.29) | 18.2507 |
| 2000's | 14 (41.18) | 29.6817 |
| 2010's | 5 (14.71) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Oster, G | 1 |
| Lamerato, L | 1 |
| Glass, AG | 1 |
| Richert-Boe, KE | 1 |
| Lopez, A | 1 |
| Chung, K | 1 |
| Richhariya, A | 1 |
| Dodge, T | 1 |
| Wolff, GG | 1 |
| Balakumaran, A | 1 |
| Edelsberg, J | 1 |
| Huang, CY | 1 |
| Wang, L | 1 |
| Feng, CJ | 1 |
| Yu, P | 1 |
| Cai, XH | 1 |
| Yao, WX | 1 |
| Xu, Y | 1 |
| Liu, XK | 1 |
| Zhu, WJ | 1 |
| Wang, Y | 1 |
| Zhou, J | 1 |
| Lu, Y | 1 |
| Wang, YS | 1 |
| Dong, M | 1 |
| Feng, FY | 1 |
| Zhang, Y | 1 |
| Xie, GR | 1 |
| Wang, YJ | 1 |
| Liu, JW | 1 |
| Song, ST | 1 |
| Zhou, QH | 1 |
| Ren, J | 2 |
| Jiao, SC | 1 |
| Li, J | 1 |
| Wang, XW | 1 |
| Chen, Q | 1 |
| Wang, ZH | 1 |
| Xu, N | 1 |
| Feng, JF | 1 |
| Crawford, BS | 1 |
| McNulty, RM | 1 |
| Kraut, EH | 1 |
| Turowski, RC | 1 |
| Spizzo, G | 1 |
| Seeber, A | 1 |
| Mitterer, M | 1 |
| Heras, P | 1 |
| Hatzopoulos, A | 1 |
| Heras, V | 1 |
| Kritikos, N | 1 |
| Karagiannis, S | 1 |
| Kritikos, K | 1 |
| Hassan, BA | 1 |
| Yusoff, ZB | 1 |
| Hassali, MA | 1 |
| Othman, SB | 1 |
| Weiderpass, E | 1 |
| Rai, Y | 1 |
| Sagara, Y | 2 |
| Takahama, T | 1 |
| Ando, M | 1 |
| Wang, DJ | 1 |
| Liu, HQ | 1 |
| Chen, YL | 1 |
| Zhan, QY | 1 |
| Cai, Y | 1 |
| Liu, MZ | 1 |
| Saba, N | 1 |
| Khuri, F | 1 |
| Andritzky, B | 1 |
| Schuch, G | 1 |
| Thoem, I | 1 |
| Goern, M | 1 |
| Brandl, S | 1 |
| Bokemeyer, C | 1 |
| Laack, E | 1 |
| McKeage, K | 1 |
| Plosker, GL | 1 |
| Kijima, T | 1 |
| Fujii, Y | 1 |
| Suyama, T | 1 |
| Okubo, Y | 1 |
| Yonese, J | 1 |
| Fukui, I | 1 |
| Gucalp, R | 1 |
| Theriault, R | 1 |
| Gill, I | 1 |
| Madajewicz, S | 1 |
| Chapman, R | 1 |
| Navari, R | 1 |
| Ahmann, F | 1 |
| Zelenakas, K | 1 |
| Heffernan, M | 1 |
| Knight, RD | 1 |
| Mundy, GR | 1 |
| Iguchi, H | 2 |
| Katakami, H | 1 |
| Ichinose, Y | 1 |
| Nishi, Y | 1 |
| Tanaka, S | 1 |
| Hara, N | 2 |
| Ohta, M | 1 |
| Haji, M | 1 |
| Nawata, H | 1 |
| Kise, H | 1 |
| Kobayashi, K | 1 |
| Arima, K | 1 |
| Yanagawa, M | 1 |
| Tochigi, H | 1 |
| Kawamura, J | 1 |
| Hioki, T | 1 |
| Sugiura, Y | 1 |
| Speden, D | 1 |
| Nicklason, F | 1 |
| Francis, H | 1 |
| Ward, J | 1 |
| Nakanishi, Y | 1 |
| Takayama, K | 1 |
| Vainas, IG | 1 |
| Tsilikas, C | 1 |
| Grecu, A | 1 |
| Pasaitu, K | 1 |
| Stergiou, I | 1 |
| Kortsaris, AH | 1 |
| Endo, K | 1 |
| Katsumata, K | 1 |
| Kubodera, N | 1 |
| Teramoto, T | 1 |
| Ikeda, K | 1 |
| Fujita, T | 1 |
| Ogata, E | 1 |
| Koshida, H | 1 |
| Kametani, T | 1 |
| Masuda, S | 1 |
| Jin, M | 1 |
| Yang, B | 1 |
| Lei, L | 1 |
| Oura, S | 1 |
| Yoshimasu, T | 2 |
| Sakurai, T | 2 |
| Nakamura, T | 1 |
| Kokawa, Y | 1 |
| Matsuyama, K | 1 |
| Ohta, F | 1 |
| Naito, Y | 2 |
| Rasmuson, T | 1 |
| Kristoffersson, A | 1 |
| Boquist, L | 1 |
| Bileckot, R | 1 |
| Touazi, S | 1 |
| Auvinet, B | 1 |
| Le Lain, JC | 1 |
| Rudlowski, C | 1 |
| Rath, W | 1 |
| Becker, AJ | 1 |
| Wiestler, OD | 1 |
| Buttner, R | 1 |
| Suzuma, T | 1 |
| Yoshimura, G | 1 |
| Umemura, T | 1 |
| Tamaki, T | 1 |
| Dodwell, DJ | 1 |
| Abbas, SK | 1 |
| Morton, AR | 1 |
| Howell, A | 1 |
| Campbell, JH | 1 |
| Ralston, S | 1 |
| Boyle, IT | 1 |
| Banham, SW | 1 |
| Mann, K | 1 |
| Body, JJ | 1 |
| Borkowski, A | 1 |
| Cleeren, A | 1 |
| Bijvoet, OL | 1 |
| Heaf, JG | 1 |
| Hansen, M | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Phase I Pilot Trial to Study the Safety and Efficacy of Concomitant Radiotherapy and Zoledronic Acid for the Palliation of Bone Metastases From Breast Cancer, Prostate Cancer and Lung Cancer[NCT00264420] | Phase 1 | 4 participants (Actual) | Interventional | 2005-12-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
4 reviews available for pamidronate and Lung Neoplasms
| Article | Year |
|---|---|
The role of bisphosphonates in the management of advanced cancer with a focus on non-small-cell lung cancer. Part 1: Mechanisms of action, role of biomarkers and preclinical applications.
Topics: Antineoplastic Agents; Apoptosis; Biomarkers, Tumor; Bone Neoplasms; Carcinoma, Non-Small-Cell Lung; | 2005 |
Zoledronic acid: a pharmacoeconomic review of its use in the management of bone metastases.
Topics: Administration, Oral; Bone Density Conservation Agents; Bone Neoplasms; Bone Resorption; Breast Neop | 2008 |
[Paraneoplastic syndrome].
Topics: Alendronate; Anticoagulants; Cushing Syndrome; Diagnosis, Differential; Diphosphonates; Disseminated | 1997 |
Metastatic parathyroid carcinoma (mPCa): natural history and treatment of a case.
Topics: Antineoplastic Agents; Calcitonin; Carcinoma; Diagnosis, Differential; Diphosphonates; Humans; Lung | 1997 |
4 trials available for pamidronate and Lung Neoplasms
| Article | Year |
|---|---|
[Phase III clinical study of zoledronic acid in the treatment of pain induced by bone metastasis from solid tumor or multiple myeloma].
Topics: Adult; Aged; Analgesics; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Collage | 2008 |
A comparative study of intravenous ibandronate and pamindronate in patients with bone metastases from breast or lung cancer: effect on metastatic bone pain.
Topics: Bone Density Conservation Agents; Bone Neoplasms; Bone Resorption; Breast Neoplasms; Diphosphonates; | 2011 |
[Pamidronate in treatment of pain caused by bone metastasis].
Topics: Adult; Aged; Bone Neoplasms; Breast Neoplasms; Diphosphonates; Dose-Response Relationship, Drug; Fem | 2004 |
Treatment of cancer-associated hypercalcemia. Double-blind comparison of rapid and slow intravenous infusion regimens of pamidronate disodium and saline alone.
Topics: Adult; Breast Neoplasms; Calcium; Diphosphonates; Double-Blind Method; Drug Administration Schedule; | 1994 |
26 other studies available for pamidronate and Lung Neoplasms
| Article | Year |
|---|---|
You're the Flight Surgeon.
Topics: Adenocarcinoma; Adult; Bone Density Conservation Agents; Chemotherapy, Adjuvant; Diphosphonates; Hum | 2017 |
Use of intravenous bisphosphonates in patients with breast, lung, or prostate cancer and metastases to bone: a 15-year study in two large US health systems.
Topics: Aged; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Diphosphonates; Female; Hu | 2014 |
Bisphosphonates enhance EGFR-TKIs efficacy in advanced NSCLC patients with EGFR activating mutation: A retrospective study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Carc | 2016 |
Extended use of intravenous bisphosphonate therapy for the prevention of skeletal complications in patients with cancer.
Topics: Adult; Aged; Aged, 80 and over; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; | 2009 |
Routine use of pamidronate in NSCLC patients with bone metastasis: results from a retrospective analysis.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Bone Neoplasms; Carcinoma, Ad | 2009 |
Impact of chemotherapy on hypercalcemia in breast and lung cancer patients.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone Density Conserv | 2012 |
[Effective weekly paclitaxel therapy for massive metastatic breast cancer].
Topics: Adult; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; D | 2004 |
Long-term survival after second-line therapy with docetaxel and carboplatin and monthly pamidronic acid in a woman with metastatic non-small cell lung cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; | 2006 |
Lung and bone metastases from renal cell carcinoma responsive to bisphosphonates: a case report.
Topics: Bone Density Conservation Agents; Bone Neoplasms; Carcinoma, Renal Cell; Diphosphonates; Humans; Imi | 2008 |
Evaluation and treatment of hypercalcemia.
Topics: Adenoma; Aged; Bone Neoplasms; Carcinoma, Squamous Cell; Diagnosis, Differential; Diphosphonates; Fe | 1994 |
A case of squamous cell lung carcinoma with high concentration of parathyroid hormone-related peptide in serum and pleural effusion presenting hypercalcemia.
Topics: Blotting, Northern; Carcinoma, Squamous Cell; Chromatography, Gel; Diagnosis, Differential; Diphosph | 1993 |
[Effect of pamidronate and interferon-alpha on bone and lung metastases and hypercalcemia in a patient with renal cell carcinoma].
Topics: Antineoplastic Agents; Bone Neoplasms; Carcinoma, Renal Cell; Diphosphonates; Humans; Hypercalcemia; | 1996 |
The use of pamidronate in hypertrophic pulmonary osteoarthropathy (HPOA).
Topics: Adenocarcinoma; Aged; Carcinoma, Non-Small-Cell Lung; Diphosphonates; Fatal Outcome; Female; Humans; | 1997 |
Effect of combination treatment with a vitamin D analog (OCT) and a bisphosphonate (AHPrBP) in a nude mouse model of cancer-associated hypercalcemia.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cachexia; Calcitriol | 1998 |
[A case of lung cancer with hypercalcemia and renal failure responsive to pamidronate].
Topics: Adenocarcinoma; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Di | 1999 |
[Treatment of metastatic bone pain with Aredia(Pamidronate)].
Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Bone Neoplasms; Breast Neop | 1998 |
[Pamidronate therapy for lung cancer patients with bone metastasis].
Topics: Aged; Analgesics, Opioid; Antineoplastic Agents; Bone Neoplasms; Diphosphonates; Female; Humans; Lun | 2000 |
Positive effect of radiotherapy and surgery on hormonally active pulmonary metastases of primary parathyroid carcinoma.
Topics: Antineoplastic Agents; Calcium; Combined Modality Therapy; Diphosphonates; Female; Follow-Up Studies | 2000 |
[Analgesic effect of Pamidronate on bone pain in patient with hypertrophic pulmonary osteoarthropathy].
Topics: Anti-Inflammatory Agents; Antineoplastic Agents; Carcinoma, Squamous Cell; Diphosphonates; Drug Admi | 2001 |
Trastuzumab and breast cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2001 |
Pamidronate-induced remission of pain associated with hypertrophic pulmonary osteoarthropathy in chemoendocrine therapy-refractory inoperable metastatic breast carcinoma.
Topics: Adult; Breast Neoplasms; Diphosphonates; Female; Humans; Lung Neoplasms; Osteoarthropathy, Secondary | 2001 |
Parathyroid hormone-related protein(50-69) and response to pamidronate therapy for tumour-induced hypercalcaemia.
Topics: Adult; Aged; Aged, 80 and over; Bone Neoplasms; Breast Neoplasms; Diphosphonates; Female; Humans; Hy | 1991 |
Symptomatic hypercalcaemia in lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Calcitonin; Diphosphonates; Drug Therapy, Combination; Female; Human | 1991 |
Oral biphosphonate therapy in metastatic parathyroid carcinoma.
Topics: Diphosphonates; Female; Humans; Lung Neoplasms; Middle Aged; Neoplasm Recurrence, Local; Pamidronate | 1985 |
Treatment of malignancy-associated hypercalcemia with intravenous aminohydroxypropylidene diphosphonate.
Topics: Adult; Aged; Bone Neoplasms; Breast Neoplasms; Calcium; Cyclic AMP; Diphosphonates; Female; Head and | 1986 |
Treatment of refractory cancer-associated hypercalcemia with aminohydroxypropylidene diphosphonate.
Topics: Adenocarcinoma; Antineoplastic Agents; Diphosphonates; Female; Humans; Hypercalcemia; Lung Neoplasms | 1988 |